I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Danijela Jelovac, M.D.
Assistant Professor of Oncology
Languages: English, Serbian
Expertise: Breast Cancer, Cervical Cancer, Gynecologic Cancers, Medical Oncology, Ovarian Cancer, Uterine Cancer
Research Interests: Breast and femal reproductive cancers
Johns Hopkins Medicine - Green Spring Station
10755 Falls Road
Lutherville, MD 21093 map
Dr. Jelovac is an assistant professor of oncology with primary interest in women malignancies, particularly breast cancer and gynecological malignancies. Her clinical focus is on development of new approaches for prevention and treatment of breast and gynecologic malignancies.
A member of the American Society of Clinical Oncology, Dr. Jelovac has published numerous peer-reviewed journal articles and book chapters and has presented her work at national meetings.
- Assistant Professor of Oncology
Centers & Institutes
- MD, University of Belgrade School of Medicine Medicinski Fakultet (1999)
- Medstar Union Memorial Hospital / Internal Medicine (2008)
- Johns Hopkins University School of Medicine / Oncology (2011)
- American Board of Internal Medicine / Internal Medicine (2008)
- American Board of Internal Medicine / Medical Oncology (2011)
Research & Publications
Armstrong DK, Fujiwara K, Jelovac D. Intraperitoneal Treatment In Ovarian Cancer: The Gynecologic Oncology Group Perspective In 2012. ASCO 2012 Educational Book. p345-348.
Jelovac D, and Wolff A. HER2-positive breast cancer; refining assessment, selecting treatment and improving outcomes. Available at http://www.medscape.org/viewarticle/739002.
Jelovac D, and Armstrong D. Intraperitoneal chemotherapy in epithelial ovarian cancer: pros and cons. ESGO Textbook of Gynecological Oncology. 2012; p980-984.
Jelovac D, and Armstrong D. Role of Farletuzumab in ovarian cancer. Curr Pharm Des. 2012;18(25):3812-5.
Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, Zorzi J, Jeter S, Oliver GR, Fetting J, Emens L, Riley C, Stearns V, Diehl F, Agenendt P, Huang P, Cope L, Argani P, Murphy K, Bachman KE, Greshock J, Wolff AC, and Park BH. Detection of tumor PIK3CA status in Metastatic Breast Cancer using Peripheral Blood. Clin Cancer Res. 2012 Jun 15;18(12):3462-9. Epub 2012 Mar 15.
Jelovac D, and Wolff AC. The adjuvant treatment of HER2-positive breast cancer. Curr Treat Options Oncol. 2012 Jun;13(2):230-9.
Garay JP, Karakas B, Abukhdeir AM, Cosgrove DP, Gustin JP, Higgins MJ, Konishi H, Konishi Y, Lauring J, Mohseni M, Wang GM, Jelovac D, Weeraratna A, Sherman Baust CA, Morin PJ, Toubaji A, Meeker A, De Marzo AM, Lewis G, Subhawong A, Argani P, Park BH. The growth response to androgen receptor signaling in ERalpha negative human breast cells is dependent on p21 and mediated by MAP kinase activation. Breast Cancer Research. 2012 Feb 9;14(1):R27.
Konishi H, Mohseni M, Tamaki A, Garay JP, Croessman S, Karnan S, Wong HY, Konishi Y, Karakas B, Tahir K, Abukhdeir AM, Gustin JP, Cidado J, Wang GM, Cosgrove D, Cochran R, Jelovac D, Higgins MJ, Arena S, Lauring J, Gross AL, Heaphy C, Hosokawa Y, Gabrielson E, Meeker A, Visvanathan K, Argani P, Bachman KE, and Park BH. Mutation of a single BRCA1 allele leads to genomic instability in human breast epithelial cells. PNAS. 2011 Oct 25;108(43):17773-8. Epub 2011 Oct 10.
Jelovac D, and Armstrong D. Recent progress in understanding, diagnosis, and treatment of ovarian cancer. CA Cancer J Clin. 2011 May-Jun;61(3):183-203.
Jelovac D, and Park BH. PTEN promoter silencing and Cowden syndrome: the role of epigenetic regulation of KILLIN. JAMA. 2010 Dec 22;304(24):2744-5.
Higgins M, Beaver J, Wong HY, Gustin JP, Lauring JD, Garay JP, Konishi H, Mohseni M, Wang GM, Cidado J, Jelovac D, Cosgrove DP, Tamaki A, Abukhdeir AM, and Park BH. PIK3CA mutations and EGFR overexpression predict lithium sensitivity in human breast epithelial cells. Cancer Biol Ther2011 Feb 1;11(3):35-44.
Sabnis G, Goloubeva O, Jelovac D, Schayowitz, and Brodie A. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens. Clin Cancer Res. 2007 May 1;13(9):2751-7.
Brodie A, Sabnis G, and Jelovac D. Aromatase and breast cancer. J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):97-102.
Tang Y, Khan MA, Goloubeva O, Lee DI, Jelovac D, Brodie AM, and Hussain A. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin Cancer Res. 2006 Jan 1; 12 (1):169-74.
Zhang Y, Wang XW, Jelovac D, Nakanishi T, Yu MH, Akinmade D, Goloubeva O, Ross DD, Brodie A, and Hamburger AW. The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells. Proc Natl Acad Sci USA. 2005 July 12;102(28):9890-5. Epub 2005 Jun 30.
Brodie A, Jelovac D, Sabnis G, Long B, Macedo L, and Goloubeva O. Model systems: Mechanisms involved in the loss of sensitivity to letrozole. J Steroid Biochem Mol Biol. 2005 May; 95 (1-5):41-8.
Jelovac D, Sabnis G, Long BJ, Macedo L, Goloubeva O, and Brodie AMH. Activation of Mitogen-Activated Protein Kinase in Xenografts and Cells during Prolonged Treatment with Aromatase Inhibitor Letrozole. Cancer Res. 2005 June 15;65(12):5380-9.
Jelovac D, Macedo L, Goloubeva O, Hadratta V, and Brodie AMH. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res. 2005 June 15;65(12):5439-44.
Sabnis GJ, Jelovac D, Long B, and Brodie A. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res. 2005 May 1;65(9):3903-10.
Brodie A, Jelovac D, Macedo L, Sabnis G, Tilghman S, and Goloubeva O. Therapeutic observations in MCF-7 aromatase xenografts. Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):884s-8s.
Jelovac D, Macedo L, Handratta V, Long BJ, and Brodie AMH. Preclinical studies evaluating the anti-tumor effects of exemestane alone or combined with tamoxifen in a postmenopausal breast cancer model. Clin Cancer Res. 2004 Nov 1;10(21):7375-7381.
Handratta VD, Jelovac D, Long BJ, Kataria R, Nnane IP, Njar VC, and Brodie AM. Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model. J Steroid Biochem Mol Biol. 2004 Oct;92(3):155-65.
Nunez NP, Jelovac D, Macedo L, Berrigan D, Perkins SN, Hursting SD, Barrett JC, and Brodie A. Effects of the Antiestrogen Tamoxifen and the Aromatase Inhibitor Letrozole, on Serum Hormones and Bone Characteristics in a Preclinical Tumor Model for Breast Cancer. Clinical Cancer Research 2004 Aug 15;10(16):5375-5380.
Long BJ, Jelovac D, Handratta V, Thiantanawat A, MacPherson N, Ragaz J, Goloubeva OG, and Brodie AM. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. Journal of National Cancer Institute 2004 Mar 17;96(6):456-65.
Samsel L, Zaidel G, Drumgoole HM, Jelovac D, Drachenberg C, Rhee JG, Brodie AM, Bielawska A, and Smyth MJ. The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts. Prostate 2004 Mar 1;58(4):382-93.
de Jong PC, Blankenstein MA, Nortier JW, Slee PH, van de Ven J, van Gorp JM, Elbers JR, Schipper ME, Blijham GH, Thijssen JH, Lu Q, Jelovac D, and Brodie AM. The relationship between aromatase in primary breast tumors and response to treatment with aromatase inhibitors in advanced disease. J Steroid Biochem Mol Biol. 2003 Nov;87(2-3):149-55.
Brodie AH, Jelovac D, and Long B. The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens. Journal of Steroid Biochemistry and Molecular Biology 2003 Sep; 86 (3-5): 283-288.
Brodie AH, Jelovac D, and Long B. Treatment strategies using letrozole and tamoxifen in a xenograft model for breast cancer. Combined treatment versus alternating or sequential treatment. Am J Cancer 2003; 2 Suppl. 1: 1-6.
Brodie A, Jelovac D, and Long BJ. Predictions from a preclinical model: Studies of aromatase inhibitors and antiestrogens. Clinical Cancer Research-January 2003 (Suppl.), Vol. 9, 455-459.
Long BJ, Jelovac, D, Thiantanawat A, and Brodie AM. The effect of second-line antiestrogen therapy on breast tumor growth following first-line treatment with the aromatase inhibitor letrozole: Long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Clinical Cancer Research - July 2002, Vol. 8, 2378-2388.